Diaceutics lifted as it exceeds expectations

The share price of AIM-listed data analytics business Diaceutics (LON:DXRX) improved by 11.72% to 113.95p (as of 14:30 GMT) after revenues for the year ended 31st December climbed by 28%. Adjusted EBITDA was also ahead of expectations as it rose by 40% over the period.

CEO Peter Keeling commented: “We are pleased to have delivered on both our operational and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Group. 2019 was a key year in expanding our global footprint and deepening our service relationships with key clients and their therapy brands. These results provide a solid base for 2020 and the launch of our Nexus platform later in 2020“.